TileBio raising £2 Million seed round to transform pathology

TileBio is raising a £2 million seed round to scale its foundation model of pathology and expand its team, accelerating the journey to transform how cancer is diagnosed and treated.

Pathology underpins almost every clinical decision in cancer care, yet the discipline is under immense strain. Demand for diagnosis is rising, while the global shortage of pathologists grows more acute. At the same time, AI in pathology has struggled to move beyond narrow, task-specific tools because it has been constrained by one bottleneck: the dependence on human-labelled data. Labels are slow, costly, and introduce bias.

TileBio has developed a different way forward. Our system learns directly from the data itself, creating the first foundation model based on a vocabulary of morphology. Instead of being told what to look for, the model discovers its own “words” — clusters of cellular and tissue patterns that recur across patients. Slides can then be read as documents, with these words forming the basis for understanding the spatial and contextual relationships that define disease.

This creates an abstraction layer for pathology: a standardised interface between the complexity of human tissue and the software tools built on top. Just as operating systems unlocked decades of innovation in computing by standardising the interface with hardware, our morphology-based language does the same for pathology, opening the door to powerful new applications.

These applications include:

• Clinical triage – accelerating cancer screening by automatically detecting malignancies across whole slide images.
• Biomarker discovery – revealing hidden morphological signals linked to patient outcomes and therapeutic response.
• Clinical trials – optimising patient selection and monitoring by identifying subtle, predictive tissue features.

A further differentiator is our access to large-scale, real-world pathology data through NHS partnerships. While other models have been trained on fragmented or private datasets, ours is rooted in the everyday clinical slides used by the health service. This ensures diversity and clinical realism, making our outputs more robust and more directly translatable into practice. The dataset is not unparalleled in size, but its provenance and quality give it unique value.

The £2 million seed round will allow us to scale the model to the next level and grow our team. By expanding our compute capacity, refining our algorithms, and adding key hires in engineering and clinical engagement, we will be ready to bring early clinical prototypes and pharmaceutical collaborations to market.

TileBio is headquartered in Scotland and led by a founding team with deep expertise in AI, digital pathology, and oncology. Together, we are building the foundation for the next generation of diagnostic and discovery tools.

If you are an investor interested in joining us to build the future of pathology, please get in touch below.